SS-31 (Elamipretide) and the FDA Approval for Barth Syndrome

In September 2025, the U.S. Food and Drug Administration granted elamipretide accelerated approval as the first approved therapy for Barth syndrome. The drug is marketed as FORZINITY by Stealth BioTherapeutics. For patients with this rare mitochondrial disease, this is an important regulatory step, even though the approval is explicitly tied to further confirmation of clinical benefit.

For peptide research, the decision is relevant primarily because elamipretide is a mitochondria-targeted tetrapeptide. It should not, however, be over-interpreted: the FDA did not rely on broad, placebo-controlled evidence of efficacy across multiple functional endpoints but on an intermediate clinical endpoint.

What Is Barth Syndrome?

Barth syndrome (BTHS) is a rare X-linked genetic disorder caused by mutations in the TAFAZZIN gene. The gene encodes an enzyme important for the remodelling of cardiolipin, a central phospholipid of the inner mitochondrial membrane.

Typical clinical features include:

• Cardiomyopathy (dilated or hypertrophic)
• Skeletal myopathy and exercise intolerance
• Neutropenia
• Growth delay and fatigue

The disease predominantly affects male patients. Prior to the approval of elamipretide, treatment consisted essentially of supportive and symptom-oriented therapy.

How Elamipretide Works

Elamipretide (D-Arg-2',6'-Dimethyltyrosine-Lys-Phe-NH2) is a tetrapeptide that accumulates at the inner mitochondrial membrane. Its mechanism of action focuses on interaction with cardiolipin.

Cardiolipin and Mitochondrial Function

Preclinical work has described that elamipretide binds to cardiolipin, can stabilise cristae structure, and may support the organisation of protein complexes in the electron transport chain. This underpins the hypothesis that the agent could improve mitochondrial energy production and reduce oxidative stress.

Not a Classical Antioxidant

Elamipretide is often distinguished from general antioxidants because the approach targets the mitochondrial membrane and its lipid environment. The clinical relevance of this in individual indications must, however, be demonstrated separately for each disease.

The Clinical Evidence Underlying the FDA Approval

The FDA prescribing information states that elamipretide in the randomised, placebo-controlled study phase was not superior to placebo on the primary endpoints of the 6-minute walk test and total fatigue score. The accelerated approval instead rests on changes in knee extensor strength as an intermediate clinical endpoint.

The approval decision was not based on positive efficacy signals from the randomised study phase for knee extensor strength. According to the FDA label, increases in knee extensor strength were observed in the open-label extension. This is regulatorily significant: under Accelerated Approval, the FDA assumes the endpoint is reasonably likely to predict clinical benefit but requires subsequent confirmation.

Key points from the FDA documentation:

• The controlled study showed no superiority over placebo on the 6-minute walk test and the total fatigue score.
• The prescribing information describes increases in knee extensor strength in the open-label extension, not a comprehensive, multi-endpoint confirmed efficacy finding.
• Common adverse events were primarily injection-site reactions.
• The approval applies to adults and children with a body weight of at least 30 kg.

Implications for Research and Development

The FDA decision is of interest for mitochondrial medicine because an intermediate clinical endpoint in a rare disease was accepted for accelerated approval. That is not a free pass for similar programmes but illustrates the kind of evidence that can be regulatorily viable in orphan indications under certain conditions.

For the development of further mitochondria-directed peptides, the key takeaways are:

• Mechanisms of action need to be linked to robust clinical endpoints.
• Open-label data can play a role but do not replace a later confirmatory study.
• Efficacy claims should remain closely tied to the actual approval basis.

What This Means for SS-31 and Related Programmes

The approval of elamipretide has increased interest in mitochondrial peptides. At the same time, it remains open in which further indications the mechanism of action can be convincingly demonstrated clinically. Programmes in areas such as heart failure, primary mitochondrial myopathies, or age-associated diseases must be evaluated separately; established efficacy for other applications cannot be inferred from the Barth syndrome approval.

For potential follow-on programmes or chemically modified derivatives: improvements in bioavailability, tissue distribution, or half-life are plausible development targets but not evidence of therapeutic benefit. Robust clinical data remain the deciding factor.

Conclusion

The FDA approval of elamipretide for Barth syndrome is medically and regulatorily significant but should be described precisely. It is based on an Accelerated Approval using knee extensor strength as an intermediate clinical endpoint, not on placebo-controlled superiority across the primary functional endpoints of the randomised study. That is precisely why the case is of interest to observers of peptide and mitochondrial research.

SS-31longevity

Mitochondria-targeted tetrapeptide (Elamipretide) that stabilizes cardiolipin and prevents ROS formation at the source.

---

References

1. U.S. Food and Drug Administration. "FDA grants accelerated approval to first treatment for Barth syndrome." September 19, 2025. FDA Press Release

2. U.S. Food and Drug Administration. FORZINITY (elamipretide) prescribing information. 2025. FDA Label / Prescribing Information

3. AlShaer D, et al. "2025 FDA TIDES (Peptides and Oligonucleotides) Harvest." Pharmaceuticals (Basel). 2026;19(2):244. PubMed

4. Tarantini S, et al. "Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide)." GeroScience. 2025. PubMed

---

This article is intended solely for information and contextualisation of published sources. Elamipretide is approved in the United States as a drug for Barth syndrome; statements in this article do not constitute medical advice.